News and Comments

Why We Are Ignoring the Temporary Selling of NKTR. See Also: Agenus Adjuvant in GSK Successful Shingles Vaccine

  Wednesday, October 19, 2016

There is nothing wrong with Nektar Therapeutics (NKTR). The stock is temporarily underperforming as traders are practicing their conviction that they must sell when a firm finances through dilution. The traders practice this law of thumb regardless of whether the financing aims at bringing wealth or invites for a catastrophe. We believe Nektar is walking the road towards creating wealth and growth through continued development of breakthrough products.    More...

Nektar Therapeutics: Crossing the Barriers and Sailing into the Future

  Tuesday, September 06, 2016

Filled with high hopes and great enthusiasm, we are following up on Nektar’s (NKTR) immunotherapy product NKTR-214, which is in trials by Mayo Clinic and MD Anderson cancer center. The product is a CD122-biased agonist designed to stimulate the patient's own immune system to kill tumor cells. The technology behind the molecule “targeted polymer conjugate technology” has been validated time and time again in clinical trials and in approved drugs marketed by Nektar partners mainly large pharmaceutical firms.  NKTR-214 uses Nektar's this technology to enable preferential activation of immunostimulatory IL-2 receptors. It is a novel mechanism of action in immunotherapy, which is what is attracting us to the drug, knowing in fact that existing IL-2 therapy activates both immunosuppressive as well as immune-stimulatory receptors, which has limited its utility in clinical settings before the surfacing of NKTR-214. More...

Nectar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...


  Monday, August 04, 2014

What’s In the Agenda? Technically-oriented analysts sometimes boost small development-stage stocks on news that are not what we meant to hear when we picked these firms to invest in. Although we appreciate the rallying of stocks for whatever reasons, our choice of firms for investment purpose  is based primarily on their validated far-reaching technologies; their pipeline promising products and the professionalism of their management teams.     More...

Recent Postings



Roche (RHHBY) CEMPRA (CEMP) Spike Therapeutics (ONCE) ISIS (ISIS) Dynavax (DVAX) Biogen Idec (BIIB) Bellicum (BLCM) Seattle Genetics (SGEN) Cytokinetics (CYTK) NEKTAR (NKTR)) PTC Therapeutics (PTCT) Agenus (AGEN Rapamune Incyte (INCY) Ariad (ARIA) Mirati Therapeutics (MRTX) SUNESIS PHARMACEUTICALS (SNSS) Pluristem (PSTI) PORTOLA (PTLA) SYNTA (SNTA) ACADIA (ACAD) Merck (MRK) Zerenex Ziofpharm (ZIOP) Sanofi-Aventis (SAN) Ridaforolimus ZALTRAP™ Inovio (INO) Prolor Biotech (PBTH) Micromet (MITI) AGOS (ARGS) Velcade (bortezomib) Theravance Bio Pharma (TBPH) Galena (GALE) VANDA (VNDA) HALOZYME (HALO) Anacor (ANAC) Advaxis (ADXS) TOKAI (TKAOI) Gilead (GILD) Telaprevir INNOVIVA (INVA) Aimmune Therapeutics (AIMT) ABBVIE (ABBV) Sangamo (SGMO) Intercept (ICPT) CRISPR Therapeutics (CRSP) Sarepta (SRPT) Anadys (ANDS) KITE (KITE) Endometrial Cancer ADVENTRIX (ANX) Sanofi (SNA) Tysabri Bristol-Myers Squibb (BMY) Auspex (ASPX) Intermune (ITMN) Idenix (IDIX) Abbott Laboratories (ABT) Trastuzumab-DM1 Human Genome Sciences (HGSI) Roche (ROCHE) RenenxBio (RGNX) AstraZeneca (AZN) Adaptimmune (ADAP) Ocular Therapeutix (OCUL) Prosensa (RNA) SERES THERAPEUTICS (MCRB) Onyx (ONXX) REGULUS (RGLS) Vertex (VRTX) Valeant Pharmaceuticals International (VRX) GUARDIAN HEALTH Elan (ELN) Illumina (ILMN) Dendreon (DNDN) galapagos (GLPG) MODERNA Editas (EDIT) NANTKWEST (NK) Global Cell Therapeutics (GBT) NOVOCURE (NVCR) KERYX (KERX) Benlysta (belimumab) ImmunoGen (IMGN) AERIE PHARMACEUTICALS Sequenom (SQNM) Theravance (THRX) Jazz Pharmaceuticals (JAZZ) Regeneron (REGN) Sanofi (SNY) BIOMARIN (BMRN) Intrexon (XON) ARCA (ABIO) CompuGen (CGEN) Human Longevity (HLI) IDERA (IDRA) Vitae Pharmaceuticals (VTAE) Agenus (AGEN) Amgen (AMGN) Genentech OSI (OSIP) ARGOS (ARGS) Array Pharmaceuticals (ARRY) Alder Biopharmaceuticals (ALDR) Ionis (IONS) Biocryst (BCRX) Xoma (XOMA) Herceptin JUNO (JUNO) C4 Therapeutics Exelixis (EXEL) GlaxoSmithKline (GSK) Alnylam (ALNY) Revlimid (lenolidamide) Multiple Myeloma